Interventional treatments for hypertrophic cardiomyopathy

Cardiovasc Ther. 2012 Jun;30(3):e107-14. doi: 10.1111/j.1755-5922.2010.00229.x. Epub 2011 Jul 31.

Abstract

Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiac disorder. This autosomal dominant condition is defined by left ventricular hypertrophy and associated with functional limitation and premature death. In fact, many individuals are asymptomatic and the annual mortality in most modern series is 1% or less. However, severe symptoms may develop at any age, and the risk of premature death from arrhythmia, stroke, and progressive systolic impairment may complicate asymptomatic disease. The clinical management of patients with HCM therefore encompasses (1) genetic counseling including discussion of indications for genetic testing and cascade family screening, (2) assessment of prognostic risk from ventricular arrhythmia, stroke, and heart failure, and (3) symptom management. This article describes the interventional treatments in the management of severe symptoms associated with left ventricular outflow tract obstruction (LVOTO).

Publication types

  • Review

MeSH terms

  • Ablation Techniques* / adverse effects
  • Cardiac Pacing, Artificial* / adverse effects
  • Cardiac Surgical Procedures* / adverse effects
  • Cardiomyopathy, Hypertrophic / diagnosis
  • Cardiomyopathy, Hypertrophic / etiology
  • Cardiomyopathy, Hypertrophic / genetics
  • Cardiomyopathy, Hypertrophic / mortality
  • Cardiomyopathy, Hypertrophic / therapy*
  • Genetic Predisposition to Disease
  • Humans
  • Risk Assessment
  • Risk Factors
  • Treatment Outcome
  • Ventricular Outflow Obstruction / diagnosis
  • Ventricular Outflow Obstruction / etiology
  • Ventricular Outflow Obstruction / mortality
  • Ventricular Outflow Obstruction / therapy*